Caribou Biosciences Inc(NASDAQ:CRBU) 
Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Website: https://www.cariboubio.com/
Founded: 2011
CEO / Co-Founder: Rachel Haurwitz
Sector:
Industry:
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
licensing and other third-party revenue | 2,397,000 | |||||||||||||||||||
operating expenses: | ||||||||||||||||||||
research and development | 20,611,000 | 23,815,000 | 22,401,000 | 27,692,000 | 35,531,000 | 30,464,000 | 30,421,000 | 35,480,000 | 33,788,000 | 31,279,000 | 28,584,000 | 26,503,000 | 25,709,000 | 25,736,000 | 19,991,000 | 22,579,000 | 13,924,000 | 15,111,000 | 15,833,000 | 12,327,000 |
general and administrative | 8,066,000 | 8,579,000 | 9,197,000 | 10,403,000 | 9,735,000 | 10,488,000 | 9,841,000 | 11,485,000 | 14,643,000 | 9,721,000 | 9,711,000 | 10,120,000 | 8,909,000 | 8,534,000 | 9,849,000 | 10,044,000 | 9,593,000 | 7,853,000 | 6,760,000 | 5,113,000 |
total operating expenses | 28,677,000 | 32,394,000 | 31,598,000 | 50,245,000 | 45,266,000 | 40,952,000 | 40,262,000 | 46,965,000 | 48,431,000 | 41,000,000 | 38,295,000 | 36,623,000 | 34,618,000 | 34,270,000 | 29,840,000 | 32,623,000 | 23,517,000 | 22,964,000 | 22,593,000 | 17,440,000 |
income from operations | -26,280,000 | -28,453,000 | -29,400,000 | -47,578,000 | -42,913,000 | -38,875,000 | -38,238,000 | -43,501,000 | -46,002,000 | -37,442,000 | -14,633,000 | -32,868,000 | -31,116,000 | -30,578,000 | -26,537,000 | -28,431,000 | -20,853,000 | -20,405,000 | -18,616,000 | -15,964,000 |
yoy | -38.76% | -26.81% | -23.11% | 9.37% | -6.71% | 3.83% | 161.31% | 32.35% | 47.84% | 22.45% | -44.86% | 15.61% | 49.22% | 49.86% | 42.55% | 78.09% | ||||
qoq | -7.64% | -3.22% | -38.21% | 10.87% | 10.39% | 1.67% | -12.10% | -5.44% | 22.86% | 155.87% | -55.48% | 5.63% | 1.76% | 15.23% | -6.66% | 36.34% | 2.20% | 9.61% | 16.61% | |
other income | 1,195,000 | 2,200,000 | 1,852,000 | 2,187,000 | 2,588,000 | 3,040,000 | 3,732,000 | 4,111,000 | 4,465,000 | 4,822,000 | 4,774,000 | 3,048,000 | 2,832,000 | 2,331,000 | 1,466,000 | 698,000 | 13,000 | 23,000 | 25,000 | |
total other income | 1,195,000 | 1,415,000 | 1,852,000 | -6,520,000 | 2,922,000 | 3,376,000 | 3,554,000 | 5,804,000 | 4,768,000 | 3,130,000 | 4,631,000 | 3,349,000 | 3,072,000 | 3,659,000 | -110,000 | 1,734,000 | 1,765,000 | 2,247,000 | -2,358,000 | 1,653,000 |
net income | -25,085,000 | -26,488,000 | -27,548,000 | -54,098,000 | -39,991,000 | -35,490,000 | -34,684,000 | -37,697,000 | -41,234,000 | -34,505,000 | -10,002,000 | -29,519,000 | -28,044,000 | -26,989,000 | -26,647,000 | -26,697,000 | -19,088,000 | |||
yoy | -37.27% | -25.36% | -20.57% | 43.51% | -3.01% | 2.85% | 246.77% | 27.70% | 47.03% | 27.85% | -62.46% | 10.57% | 46.92% | |||||||
qoq | -5.30% | -3.85% | -49.08% | 35.28% | 12.68% | 2.32% | -7.99% | -8.58% | 19.50% | 244.98% | -66.12% | 5.26% | 3.91% | 1.28% | -0.19% | 39.86% | ||||
other comprehensive loss | ||||||||||||||||||||
net unrealized loss on available-for-sale marketable securities, net of tax | -126,000 | -88,000 | -475,000 | -454,000 | -492,000 | -954,000 | ||||||||||||||
net comprehensive loss | -25,211,000 | -26,478,000 | -27,495,000 | -54,225,000 | -40,079,000 | -36,024,000 | -33,576,000 | -37,694,000 | -41,586,000 | -33,494,000 | -9,847,000 | -29,925,000 | -27,256,000 | -26,472,000 | -27,101,000 | -27,189,000 | -20,042,000 | |||
net income per share | -0.26 | -0.28 | -0.3 | -0.58 | -0.43 | -0.39 | -0.38 | -0.42 | -0.46 | -0.4 | -0.12 | -0.48 | -0.46 | -0.45 | -0.44 | -0.44 | -0.32 | 0.09 | -0.46 | -1.39 |
weighted-average common shares outstanding, basic and diluted | 95,861,716 | 93,389,283 | 93,293,099 | 93,028,698 | 92,679,493 | 90,317,925 | 90,455,900 | 90,340,932 | 89,302,937 | 73,807,597 | 83,783,992 | 61,417,934 | 61,186,514 | 60,801,133 | 60,886,921 | 60,757,689 | 60,546,170 | 31,663,243 | 45,889,646 | 10,261,770 |
licensing and collaboration revenue | 3,941,000 | 2,198,000 | 2,667,000 | 2,353,000 | 2,077,000 | 2,024,000 | 3,464,000 | 2,429,000 | 3,558,000 | 23,662,000 | 3,755,000 | 3,502,000 | 3,692,000 | 3,303,000 | 4,192,000 | 2,664,000 | 2,559,000 | 3,977,000 | 1,476,000 | |
impairment charges | 12,150,000 | |||||||||||||||||||
other income: | ||||||||||||||||||||
impairment of equity investment | -9,158,000 | |||||||||||||||||||
change in fair value of the mskcc success payments liability | 196,250 | 451,000 | 334,000 | 220,000 | -164,000 | 1,795,000 | 303,000 | -1,683,000 | -139,000 | 279,000 | 255,000 | 1,388,000 | -1,607,000 | 1,052,000 | 1,596,000 | 2,158,000 | -2,403,000 | |||
other comprehensive income | ||||||||||||||||||||
net unrealized gain on available-for-sale marketable securities, net of tax | 10,000 | 53,000 | -127,000 | -534,000 | 1,108,000 | 3,000 | -352,000 | 134,250 | 155,000 | -406,000 | 788,000 | |||||||||
change in fair value of equity securities | -29,000 | -14,000 | -102,000 | -9,000 | -4,000 | 22,000 | -15,000 | -60,000 | 31,000 | -16,000 | -88,000 | |||||||||
other comprehensive income: | ||||||||||||||||||||
gain on extinguishment of ppp loan | 1,584,000 | |||||||||||||||||||
other comprehensive loss: | ||||||||||||||||||||
other income - net | 257,000 | |||||||||||||||||||
interest income | 76,000 | 22,000 | 46,000 | |||||||||||||||||
interest expense | -2,000 | |||||||||||||||||||
net loss before provision for income taxes | -18,158,000 | -20,974,000 | -14,311,000 | |||||||||||||||||
benefit from income taxes | ||||||||||||||||||||
net loss and comprehensive loss | -12,111,000 | -20,974,000 | -14,311,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||
current assets | ||||||||||||||||||||
cash and cash equivalents | 12,057,000 | 12,360,000 | 11,144,000 | 25,201,000 | 29,417,000 | 16,293,000 | 31,970,000 | 37,866,000 | 49,400,000 | 51,162,000 | 104,058,000 | 66,194,000 | 52,744,000 | 58,338,000 | 82,085,000 | 112,146,000 | 147,630,000 | 240,420,000 | 435,310,000 | 129,524,000 |
marketable securities, short-term | 105,569,000 | 126,980,000 | 136,115,000 | 158,747,000 | 179,048,000 | 193,244,000 | 196,208,000 | 223,783,000 | 244,588,000 | 277,665,000 | 234,430,000 | 193,038,000 | 175,794,000 | 189,325,000 | 211,284,000 | 227,778,000 | 206,101,000 | 135,412,000 | ||
accounts receivable | 227,000 | 69,000 | 242,000 | 71,000 | 88,000 | 265,000 | 184,000 | 215,000 | 917,000 | 148,000 | 1,133,000 | 766,000 | 1,533,000 | 202,000 | 397,000 | 524,000 | 374,000 | 1,153,000 | 578,000 | 2,000 |
contract assets | 691,000 | 1,006,000 | 860,000 | 753,000 | 808,000 | 1,158,000 | 798,000 | 972,000 | 971,000 | 1,425,000 | 1,658,000 | 1,481,000 | 1,639,000 | 2,247,000 | 1,899,000 | 2,093,000 | 1,494,000 | 1,488,000 | 1,853,000 | 830,000 |
other receivables | 1,445,000 | 1,904,000 | 1,828,000 | 1,956,000 | 1,844,000 | 1,828,000 | 1,683,000 | 1,729,000 | 1,725,000 | 2,286,000 | 2,345,000 | 1,495,000 | 1,670,000 | 2,215,000 | 2,699,000 | 3,094,000 | 4,169,000 | 5,483,000 | 5,354,000 | 7,575,000 |
prepaid expenses and other current assets | 2,392,000 | 2,913,000 | 5,317,000 | 5,778,000 | 6,118,000 | 6,589,000 | 6,583,000 | 6,317,000 | 6,913,000 | 6,155,000 | 7,069,000 | 5,564,000 | 6,110,000 | 7,921,000 | 8,558,000 | 7,293,000 | 8,242,000 | 7,236,000 | 5,952,000 | 5,036,000 |
total current assets | 122,381,000 | 145,232,000 | 155,506,000 | 192,506,000 | 217,323,000 | 219,377,000 | 237,426,000 | 270,882,000 | 304,514,000 | 338,841,000 | 350,693,000 | 268,538,000 | 239,490,000 | 260,248,000 | 306,922,000 | 352,928,000 | 368,010,000 | 391,192,000 | 449,047,000 | 142,967,000 |
non-current assets | ||||||||||||||||||||
marketable securities, long-term | 1,001,000 | 3,505,000 | 11,953,000 | 3,987,000 | 39,849,000 | 52,837,000 | 50,124,000 | 51,938,000 | 43,577,000 | 58,219,000 | 33,289,000 | 62,452,000 | 69,373,000 | 49,221,000 | 26,152,000 | 37,092,000 | 37,676,000 | |||
property and equipment | 6,123,000 | 6,760,000 | 7,598,000 | 8,179,000 | 18,519,000 | 19,281,000 | 19,565,000 | 19,876,000 | 19,167,000 | 18,270,000 | 16,598,000 | 15,429,000 | 12,646,000 | 10,678,000 | 8,959,000 | 8,006,000 | ||||
operating lease, right of use assets | 17,356,000 | 17,670,000 | 16,004,000 | 16,461,000 | 19,520,000 | 20,009,000 | 20,493,000 | 21,134,000 | 21,659,000 | 22,182,000 | 22,680,000 | 23,206,000 | 23,715,000 | 24,230,000 | 24,626,000 | 25,250,000 | ||||
other assets | 2,137,000 | 2,200,000 | 3,780,000 | 3,625,000 | 5,042,000 | 5,521,000 | 4,741,000 | 1,636,000 | 1,794,000 | 1,586,000 | 1,568,000 | 1,419,000 | 1,476,000 | 1,538,000 | 1,336,000 | 1,303,000 | 1,464,000 | 975,000 | 810,000 | 3,396,000 |
total assets | 148,998,000 | 175,367,000 | 194,984,000 | 220,903,000 | 273,656,000 | 313,313,000 | 344,334,000 | 372,938,000 | 406,825,000 | 432,209,000 | 457,521,000 | 349,647,000 | 347,462,000 | 373,765,000 | 398,823,000 | 421,367,000 | 445,997,000 | 442,356,000 | 461,960,000 | 158,397,000 |
liabilities and stockholders’ equity | ||||||||||||||||||||
current liabilities | ||||||||||||||||||||
accounts payable | 3,503,000 | 5,783,000 | 3,804,000 | 3,243,000 | 3,873,000 | 2,476,000 | 2,704,000 | 3,227,000 | 5,940,000 | 3,120,000 | 2,377,000 | 4,433,000 | 2,651,000 | 1,146,000 | 1,228,000 | 426,000 | 1,814,000 | 3,990,000 | 3,482,000 | 4,029,000 |
accrued expenses and other current liabilities | 13,889,000 | 16,535,000 | 19,350,000 | 20,528,000 | 19,888,000 | 23,620,000 | 25,448,000 | 23,626,000 | 18,990,000 | 21,135,000 | 18,230,000 | 15,901,000 | 12,544,000 | 16,079,000 | 14,638,000 | 14,910,000 | 11,190,000 | 13,136,000 | 13,930,000 | 13,297,000 |
operating lease liabilities, current | 1,287,000 | 1,201,000 | 2,687,000 | 2,287,000 | 1,901,000 | 1,426,000 | 1,178,000 | 1,262,000 | 1,264,000 | 1,200,000 | ||||||||||
deferred revenue | 994,000 | 1,895,000 | 2,217,000 | 2,829,000 | 2,829,000 | 3,129,000 | 2,829,000 | 2,829,000 | 2,827,000 | 2,847,000 | 2,826,000 | 12,962,000 | 10,883,000 | 9,937,000 | 12,036,000 | 12,642,000 | 12,838,000 | 8,703,000 | 8,746,000 | 8,681,000 |
total current liabilities | 19,673,000 | 25,414,000 | 28,058,000 | 28,887,000 | 28,491,000 | 30,651,000 | 32,159,000 | 30,944,000 | 29,021,000 | 28,302,000 | 24,572,000 | 34,375,000 | 27,100,000 | 28,128,000 | 28,814,000 | 28,855,000 | 26,667,000 | 25,829,000 | 26,158,000 | 26,007,000 |
long-term liabilities | ||||||||||||||||||||
deferred revenue, net of current portion | 1,648,000 | 1,752,000 | 1,756,000 | 1,772,000 | 2,621,000 | 3,317,000 | 3,947,000 | 4,604,000 | 5,428,000 | 6,102,000 | 6,728,000 | 18,162,000 | 13,911,000 | 15,954,000 | 15,423,000 | 15,626,000 | 17,326,000 | 22,032,000 | 23,022,000 | 24,208,000 |
operating lease liabilities, non-current | 25,659,000 | 26,026,000 | 22,777,000 | 23,564,000 | 24,323,000 | 25,061,000 | 25,463,000 | 25,528,000 | 25,895,000 | 25,908,000 | ||||||||||
total liabilities | 46,980,000 | 53,192,000 | 53,139,000 | 54,771,000 | 56,434,000 | 60,362,000 | 63,131,000 | 62,474,000 | 63,536,000 | 63,808,000 | 59,253,000 | 80,189,000 | 69,190,000 | 72,894,000 | 74,709,000 | 73,478,000 | 74,200,000 | 54,531,000 | 57,559,000 | 55,938,000 |
commitments and contingencies | ||||||||||||||||||||
stockholders’ equity | ||||||||||||||||||||
common stock, par value 0.0001... | 10,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 9,000 | 8,000 | 8,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 1,000 |
additional paid-in-capital | 723,631,000 | 718,578,000 | 711,770,000 | 708,562,000 | 705,427,000 | 701,077,000 | 693,305,000 | 688,990,000 | 684,121,000 | 667,648,000 | 664,021,000 | 525,366,000 | 504,255,000 | 499,598,000 | 496,369,000 | 493,043,000 | 489,762,000 | 485,748,000 | 483,710,000 | 10,649,000 |
accumulated other comprehensive income | -23,000 | 103,000 | 93,000 | 40,000 | 167,000 | 255,000 | 789,000 | -319,000 | -322,000 | 30,000 | ||||||||||
accumulated deficit | -621,600,000 | -596,515,000 | -570,027,000 | -542,479,000 | -488,381,000 | -448,390,000 | -412,900,000 | -378,216,000 | -340,519,000 | -299,285,000 | -264,780,000 | -254,778,000 | -225,259,000 | -197,215,000 | -170,226,000 | -143,579,000 | -116,882,000 | -97,794,000 | -79,315,000 | -58,341,000 |
total stockholders’ equity | 102,018,000 | 122,175,000 | 141,845,000 | 166,132,000 | 217,222,000 | 252,951,000 | 281,203,000 | 310,464,000 | 343,289,000 | 368,401,000 | 398,268,000 | 269,458,000 | 278,272,000 | 300,871,000 | 324,114,000 | 347,889,000 | 371,797,000 | 387,825,000 | 404,401,000 | |
total liabilities and stockholders’ equity | 148,998,000 | 175,367,000 | 194,984,000 | 220,903,000 | 273,656,000 | 313,313,000 | 344,334,000 | 372,938,000 | 406,825,000 | 432,209,000 | 457,521,000 | 349,647,000 | 347,462,000 | 373,765,000 | 398,823,000 | 421,367,000 | 445,997,000 | |||
current assets: | ||||||||||||||||||||
investments in equity securities | 143,000 | 132,000 | 9,265,000 | 9,276,000 | 9,272,000 | 9,286,000 | 7,753,000 | 7,753,000 | 7,763,000 | 7,766,000 | 7,683,000 | 7,698,000 | 7,759,000 | 7,728,000 | 7,666,000 | 7,626,000 | 7,626,000 | 7,626,000 | ||
current liabilities: | ||||||||||||||||||||
mskcc success payments liability | 451,000 | 785,000 | 1,005,000 | 841,000 | 2,636,000 | 2,939,000 | 1,256,000 | 1,117,000 | 1,396,000 | 1,651,000 | 3,039,000 | 1,432,000 | 2,484,000 | 4,080,000 | 6,238,000 | |||||
deferred tax liabilities | 548,000 | 548,000 | 548,000 | 548,000 | 557,000 | 557,000 | 556,000 | 557,000 | 381,000 | 380,000 | 382,000 | 381,000 | 475,000 | 475,000 | 476,000 | 476,000 | 155,000 | 155,000 | ||
lease liabilities, current | 1,139,000 | 1,079,000 | 1,022,000 | 966,000 | 912,000 | |||||||||||||||
lease liabilities, non-current | 26,316,000 | 26,155,000 | 26,401,000 | 26,780,000 | 26,958,000 | 27,090,000 | 27,238,000 | |||||||||||||
preferred stock, par value 0.0001... | ||||||||||||||||||||
accumulated other comprehensive loss | -981,000 | -1,136,000 | -730,000 | -1,518,000 | -2,035,000 | -1,581,000 | -1,089,000 | -135,000 | ||||||||||||
deferred rent and lease incentive liability | 2,097,000 | 1,833,000 | 1,570,000 | |||||||||||||||||
other liabilities | 9,000 | 17,000 | 153,000 | 163,000 | ||||||||||||||||
lease liabilities | 877,000 | 825,000 | ||||||||||||||||||
property and equipment - net | 6,016,000 | 4,887,000 | ||||||||||||||||||
operating lease, right of use asset | 25,749,000 | |||||||||||||||||||
liabilities, convertible preferred stock, and stockholders’ equity | ||||||||||||||||||||
promissory note — ppp loan | ||||||||||||||||||||
promissory note — ppp loan, net of current portion | ||||||||||||||||||||
convertible preferred stock, par value 0.0001... | 150,150,000 | |||||||||||||||||||
total liabilities, convertible preferred stock, and stockholders’ equity | 442,356,000 | 461,960,000 | ||||||||||||||||||
property and equipment—net | 4,477,000 | 4,408,000 | ||||||||||||||||||
liabilities, convertible preferred stock, and stockholders’ deficit | ||||||||||||||||||||
success payments liability | 3,835,000 | |||||||||||||||||||
stockholders’ deficit | ||||||||||||||||||||
total stockholders’ deficit | -47,691,000 | |||||||||||||||||||
total liabilities, convertible preferred stock, and stockholders’ deficit | 158,397,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities: | |||||||||||||||||||
net loss | -25,085,000 | -26,488,000 | -27,548,000 | -54,098,000 | -39,991,000 | -35,490,000 | -34,684,000 | -37,697,000 | -41,234,000 | -34,505,000 | -10,002,000 | -29,519,000 | -28,044,000 | -26,989,000 | -26,647,000 | -26,697,000 | -19,088,000 | -18,479,000 | -20,974,000 |
adjustments to reconcile net loss to net cash from operating activities: | |||||||||||||||||||
depreciation and amortization | 649,000 | 682,000 | 631,000 | 1,167,000 | 1,165,000 | 1,184,000 | 1,177,000 | 856,000 | 710,000 | 740,000 | 1,579,000 | 617,000 | 589,000 | 506,000 | 450,000 | 358,000 | 308,000 | 273,000 | 260,000 |
change in fair value of equity securities | 115,000 | -12,000 | -15,000 | 11,000 | -5,000 | 14,000 | 9,000 | 4,000 | -22,000 | 15,000 | 60,000 | -31,000 | 16,000 | 88,000 | |||||
stock-based compensation expense | 2,357,000 | 2,738,000 | 2,931,000 | 3,129,000 | 3,882,000 | 3,911,000 | 4,069,000 | 4,738,000 | 3,988,000 | 3,556,000 | 3,478,000 | 3,585,000 | 3,131,000 | 3,101,000 | 2,673,000 | 2,918,000 | 3,024,000 | 1,578,000 | 935,000 |
change in fair value of success payments liability | |||||||||||||||||||
accretion of discounts on investments in marketable securities | -269,000 | -160,000 | -235,000 | -293,000 | -452,000 | -1,018,000 | -1,223,000 | -946,000 | -1,539,000 | ||||||||||
non-cash lease expense | 315,000 | 422,000 | 457,000 | 475,000 | 490,000 | 483,000 | 642,000 | 524,000 | 524,000 | 497,000 | 527,000 | 509,000 | 515,000 | 397,000 | 622,000 | 500,000 | 500,000 | ||
changes in operating assets and liabilities: | |||||||||||||||||||
accounts receivable | -158,000 | 173,000 | -171,000 | 17,000 | 177,000 | -81,000 | 32,000 | 702,000 | -770,000 | 985,000 | -367,000 | 767,000 | -1,331,000 | 195,000 | 127,000 | -150,000 | 779,000 | -575,000 | -576,000 |
contract assets | 315,000 | -146,000 | -107,000 | 55,000 | 350,000 | -361,000 | 175,000 | -1,000 | 454,000 | 234,000 | -177,000 | 158,000 | 607,000 | -348,000 | 195,000 | -600,000 | -6,000 | 365,000 | -1,023,000 |
other receivables | 459,000 | -112,000 | -17,000 | -145,000 | 46,000 | -4,000 | 561,000 | 59,000 | -850,000 | 175,000 | 545,000 | 485,000 | 395,000 | 1,075,000 | 1,313,000 | -127,000 | 2,221,000 | ||
prepaid expenses and other current assets | 522,000 | 2,403,000 | 461,000 | 340,000 | 471,000 | -5,000 | -266,000 | 596,000 | -758,000 | 914,000 | -1,504,000 | 545,000 | 1,811,000 | 638,000 | -1,266,000 | 949,000 | -1,296,000 | -1,284,000 | -917,000 |
other assets | 63,000 | 1,609,000 | -155,000 | 1,417,000 | 479,000 | -780,000 | -3,105,000 | 159,000 | -209,000 | -18,000 | -149,000 | 57,000 | 62,000 | -203,000 | -35,000 | 161,000 | -487,000 | -165,000 | 0 |
accounts payable | -2,220,000 | 1,919,000 | 561,000 | -630,000 | 1,404,000 | -229,000 | -477,000 | -2,368,000 | 2,720,000 | 730,000 | -953,000 | 540,000 | 1,502,000 | -153,000 | 989,000 | -1,642,000 | -1,915,000 | 291,000 | -183,000 |
accrued expenses and other current liabilities | -2,646,000 | -2,816,000 | -1,111,000 | 688,000 | -3,101,000 | -2,207,000 | 1,578,000 | 4,967,000 | -2,204,000 | 2,895,000 | 3,279,000 | 3,707,000 | -4,138,000 | 1,044,000 | -208,000 | 3,948,000 | -2,831,000 | -574,000 | 3,846,000 |
deferred revenue, current and long-term | -1,005,000 | -326,000 | -627,000 | -849,000 | -996,000 | -330,000 | -658,000 | -821,000 | -694,000 | -606,000 | -21,568,000 | 6,328,000 | -1,097,000 | -1,567,000 | -807,000 | -1,898,000 | -572,000 | -1,032,000 | -1,122,000 |
operating lease liabilities | -281,000 | -325,000 | -389,000 | -372,000 | -263,000 | -154,000 | -149,000 | -369,000 | 51,000 | -346,000 | 220,000 | -188,000 | -323,000 | -124,000 | -97,000 | -97,000 | -85,000 | ||
net cash from operating activities | -26,984,000 | -20,824,000 | -25,185,000 | -28,258,000 | -36,725,000 | -35,470,000 | -32,661,000 | -32,866,000 | -37,203,000 | -21,379,000 | -28,788,000 | -15,185,000 | -27,939,000 | -25,044,000 | -22,376,000 | -21,873,000 | -21,673,000 | -21,389,000 | -14,967,000 |
capital expenditures | 216,000 | -115,000 | -466,000 | -927,000 | -137,000 | -475,000 | -2,917,000 | -597,000 | -2,141,000 | -6,758,000 | -1,705,000 | -317,000 | -1,757,000 | -1,304,000 | -2,620,000 | -723,000 | -685,000 | -930,000 | |
free cash flows | -20,608,000 | -25,300,000 | -28,724,000 | -37,652,000 | -35,607,000 | -33,136,000 | -35,783,000 | -37,800,000 | -23,520,000 | -35,546,000 | -16,890,000 | -28,256,000 | -26,801,000 | -23,680,000 | -24,493,000 | -22,396,000 | -22,074,000 | -15,897,000 | |
cash flows from investing activities: | |||||||||||||||||||
proceeds from maturities of marketable securities | 46,142,000 | 61,788,000 | 68,414,000 | 56,673,000 | 65,955,000 | 107,801,000 | 97,088,000 | ||||||||||||
purchases of marketable securities | -22,085,000 | -44,034,000 | -57,448,000 | -32,219,000 | -15,532,000 | -55,504,000 | -93,470,000 | -84,235,000 | -71,184,000 | -84,192,000 | -175,892,000 | -58,743,000 | -75,931,000 | -86,511,000 | -70,806,000 | -71,062,000 | -110,684,000 | ||
purchases of property and equipment | -72,000 | 216,000 | -115,000 | -418,000 | -1,042,000 | -518,000 | -673,000 | -2,241,000 | -1,448,000 | -2,277,000 | -4,752,000 | -2,553,000 | -2,031,000 | -1,757,000 | -1,354,000 | -2,620,000 | -723,000 | -685,000 | -930,000 |
net cash from investing activities | 23,985,000 | 17,970,000 | 10,851,000 | 24,036,000 | 49,381,000 | 15,930,000 | 26,521,000 | 21,200,000 | 22,956,000 | -31,474,000 | -68,476,000 | 11,064,000 | 20,703,000 | 1,170,000 | -8,339,000 | -13,973,000 | -72,107,000 | -173,961,000 | -1,930,000 |
cash flows from financing activities: | |||||||||||||||||||
proceeds from exercise of stock options | 9,000 | 0 | 0 | 130,000 | 489,000 | 460,000 | |||||||||||||
proceeds from issuances of common stock under espp | 468,000 | 0 | 277,000 | 0 | 468,000 | 1,000 | |||||||||||||
proceeds from issuances of common stock related to atm, net of offering expenses | 2,219,000 | ||||||||||||||||||
net cash from financing activities | 2,696,000 | 4,070,000 | 277,000 | 6,000 | 468,000 | 3,863,000 | 244,000 | 132,000 | 12,485,000 | -43,000 | 135,128,000 | 17,571,000 | 1,642,000 | 127,000 | 654,000 | 362,000 | 990,000 | 460,000 | 322,683,000 |
net increase in cash, cash equivalents, and restricted cash | -303,000 | -4,216,000 | 13,124,000 | -5,896,000 | 37,864,000 | -23,747,000 | -30,061,000 | -35,484,000 | -92,790,000 | -194,890,000 | 305,786,000 | ||||||||
cash, cash equivalents, and restricted cash — beginning of period | 12,406,000 | 0 | 0 | 0 | 16,339,000 | 0 | 0 | 0 | 51,208,000 | 0 | 0 | 0 | 58,384,000 | 0 | 46,000 | -46,000 | 240,466,000 | 0 | 0 |
cash, cash equivalents, and restricted cash — end of period | 12,103,000 | 1,216,000 | -14,057,000 | -4,216,000 | 29,463,000 | -15,677,000 | -5,896,000 | -11,534,000 | 49,446,000 | -52,896,000 | 37,864,000 | 13,450,000 | 52,790,000 | -23,747,000 | -30,015,000 | -35,530,000 | 147,676,000 | -194,890,000 | 305,786,000 |
reconciliation of cash, cash equivalents, and restricted cash | |||||||||||||||||||
cash and cash equivalents | 12,057,000 | 1,216,000 | -14,057,000 | -4,216,000 | 29,417,000 | -15,677,000 | -5,896,000 | -11,534,000 | 49,400,000 | -52,896,000 | 37,864,000 | 13,450,000 | 52,744,000 | -23,747,000 | -30,061,000 | -35,484,000 | 147,630,000 | -194,890,000 | 305,786,000 |
restricted cash | 46,000 | 0 | 0 | 0 | 46,000 | 0 | 0 | 0 | 46,000 | 0 | 0 | 0 | 46,000 | 0 | 0 | 0 | 46,000 | 0 | 0 |
cash, cash equivalents, and restricted cash on the balance sheet | 12,103,000 | 1,216,000 | -14,057,000 | -4,216,000 | 29,463,000 | -15,677,000 | -5,896,000 | -11,534,000 | 49,446,000 | 147,676,000 | -194,890,000 | 305,786,000 | |||||||
supplemental schedule of non-cash investing and financing activities: | |||||||||||||||||||
purchases of property and equipment included in accounts payable and accrued expenses | -48,000 | 115,000 | 381,000 | 198,000 | -676,000 | 851,000 | 136,000 | -2,006,000 | 848,000 | 1,714,000 | |||||||||
gain on disposal of fixed assets | 0 | 0 | 0 | -34,000 | |||||||||||||||
non-cash consideration for licensing and collaboration revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -77,000 | -128,000 | |||||||||
change in fair value of mskcc success payments liability | 0 | 0 | -451,000 | -334,000 | -220,000 | 164,000 | -1,795,000 | -303,000 | 1,683,000 | 139,000 | -279,000 | -255,000 | -1,388,000 | 1,607,000 | -1,052,000 | -1,596,000 | -2,158,000 | ||
acquired in-process research and development | 0 | 0 | 125,000 | 1,500,000 | 300,000 | 0 | 0 | 0 | |||||||||||
impairment charges | 0 | 0 | |||||||||||||||||
impairment of equity investment | 0 | 0 | |||||||||||||||||
deferred tax liabilities | |||||||||||||||||||
proceeds from sale of property and equipment | |||||||||||||||||||
payments to acquire in-process research and development | 0 | 0 | -125,000 | -1,500,000 | -300,000 | 0 | |||||||||||||
net decrease in cash, cash equivalents, and restricted cash | 1,216,000 | -1,762,000 | -5,594,000 | ||||||||||||||||
right-of-use-assets recognized due to lease remeasurement | |||||||||||||||||||
loss on disposal of fixed assets | 0 | ||||||||||||||||||
proceeds from sales and maturities of marketable securities | 71,939,000 | 54,995,000 | 112,168,000 | 72,360,000 | 98,665,000 | ||||||||||||||
proceeds from follow-on public offering, net of offering expenses | |||||||||||||||||||
proceeds from issuances of common stock in a private placement with pfizer | |||||||||||||||||||
supplemental cash flow information: | |||||||||||||||||||
cash paid for income taxes | 0 | 0 | 0 | 0 | |||||||||||||||
proceeds from public follow-on public offering, net of offering expenses | |||||||||||||||||||
proceeds from issuances of common stock pursuant to private placement with pfizer | |||||||||||||||||||
proceeds from exercises of stock options | |||||||||||||||||||
proceeds from issuances of common stock related to our atm, net of offering expenses | |||||||||||||||||||
offering costs included in accrued expenses | -47,000 | 44,000 | 116,000 | ||||||||||||||||
proceeds from issuance of common stock pursuant to private placement with pfizer | |||||||||||||||||||
proceeds from purchases of common stock under espp | |||||||||||||||||||
proceeds from issuance of common stock related to our atm, net of offering expenses | |||||||||||||||||||
proceeds from purchases of common stock under employee stock purchase plan | 667,000 | ||||||||||||||||||
proceeds from issuance of common stock related to our at-the-market equity offering program, net of offering expenses | 11,329,000 | ||||||||||||||||||
other liabilities | 0 | 0 | -7,000 | -8,000 | -140,000 | -8,000 | |||||||||||||
proceeds from issuance of common stock in a private placement with pfizer | 0 | -160,000 | |||||||||||||||||
proceeds from exercise of stock options and purchases of common stock under employee stock purchase plan | 70,000 | 753,000 | 236,000 | 519,000 | 127,000 | 654,000 | 362,000 | 990,000 | |||||||||||
proceeds from issuance of common stock related to at-the-market offering, net of offering expenses | 0 | -1,000 | -115,000 | 1,123,000 | |||||||||||||||
right-of-use-assets obtained in exchange for new operating lease liabilities | 0 | 0 | |||||||||||||||||
(accretion of discounts) and amortization of premiums on investments | -2,444,000 | ||||||||||||||||||
total cash, cash equivalents, and restricted cash | 37,864,000 | 13,450,000 | 52,790,000 | -30,061,000 | |||||||||||||||
acquired in-process research and development accrued | |||||||||||||||||||
amortization of investment premiums | -1,494,000 | -343,000 | 122,000 | 327,000 | |||||||||||||||
loss on disposal of property and equipment | |||||||||||||||||||
extinguishment of ppp loan and accrued interest | |||||||||||||||||||
amortization of premiums on marketable securities | |||||||||||||||||||
deferred rent and lease incentive liability | 264,000 | 171,000 | |||||||||||||||||
maturities of marketable securities | 89,738,000 | 64,121,000 | 59,709,000 | 39,300,000 | |||||||||||||||
proceeds from initial public offering of common stock, net of offering costs | 0 | ||||||||||||||||||
proceeds from issuance of series c convertible preferred stock, net of issuance costs | 0 | ||||||||||||||||||
repayment of promissory note | 0 | 0 | |||||||||||||||||
payments on capital lease | 0 | ||||||||||||||||||
purchases of property and equipment unpaid at period end | |||||||||||||||||||
conversion of convertible preferred stock to common stock at closing of initial public offering | 0 | ||||||||||||||||||
extinguishment of ppp loan | 0 | ||||||||||||||||||
acquisition of property and equipment included in accrued expenses and other current liabilities | 50,000 | ||||||||||||||||||
payment of deferred issuance costs | |||||||||||||||||||
deferred issuance costs related to initial public offering unpaid at period end | |||||||||||||||||||
interest expense | |||||||||||||||||||
initial fair value of mskcc success payments liability | |||||||||||||||||||
proceeds from sale of equity securities | |||||||||||||||||||
proceeds from ppp loan | |||||||||||||||||||
capital lease financing for purchase of assets | |||||||||||||||||||
issuance of common stock to acquire in-process research and development | |||||||||||||||||||
non-cash consideration in exchange for licensing and collaboration revenue | |||||||||||||||||||
payments to acquire in-process research & development | |||||||||||||||||||
issuance of series c convertible preferred stock | |||||||||||||||||||
proceeds from common stock options exercised | |||||||||||||||||||
principal payments for capital lease | |||||||||||||||||||
purchases of property and equipment accrued | |||||||||||||||||||
deferred issuance costs related to initial public offering accrued |